Find ORIC-101 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Oric-101, Chembl4161754, 2222344-98-9, Unii-vi6e2d3cyp, Oric101, Oric-101 [who-dd]
Molecular Formula
C34H47NO2
Molecular Weight
501.7  g/mol
InChI Key
VNLTWJIWEYPBIF-KMSLUKAPSA-N
FDA UNII
VI6E2D3CYP

ORIC-101
Glucocorticoid Receptor Antagonist ORIC-101 is a mifepristone-based steroidal glucocorticoid receptor (GR) antagonist with potential antineoplastic activity. Upon oral administration, ORIC-101 selectively binds to GRs, thereby inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers. Due to its reduced androgen receptor (AR) agonistic activity and improved cytochrome P450 2C8 (CYP2C8) and 2C9 (CYP2C9) inhibition profile, ORIC-101 may be useful in the treatment of AR-positive tumors with reduced potential for drug-drug interactions.
1 2D Structure

ORIC-101

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-13-methyl-11-[4-[methyl(propan-2-yl)amino]phenyl]-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
2.1.2 InChI
InChI=1S/C34H47NO2/c1-22(2)35(7)25-11-8-23(9-12-25)29-21-33(6)30(16-17-34(33,37)19-18-32(3,4)5)28-14-10-24-20-26(36)13-15-27(24)31(28)29/h8-9,11-12,20,22,27-31,37H,10,13-17,21H2,1-7H3/t27-,28-,29+,30-,31+,33-,34+/m0/s1
2.1.3 InChI Key
VNLTWJIWEYPBIF-KMSLUKAPSA-N
2.1.4 Canonical SMILES
CC(C)N(C)C1=CC=C(C=C1)C2CC3(C(CCC3(C#CC(C)(C)C)O)C4C2C5CCC(=O)C=C5CC4)C
2.1.5 Isomeric SMILES
CC(C)N(C)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C#CC(C)(C)C)O)[C@H]4[C@H]2[C@H]5CCC(=O)C=C5CC4)C
2.2 Other Identifiers
2.2.1 UNII
VI6E2D3CYP
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Oric-101

2. Chembl4161754

3. 2222344-98-9

4. Unii-vi6e2d3cyp

5. Oric101

6. Oric-101 [who-dd]

7. Schembl20048238

8. Bdbm50368933

9. Hy-112710

10. Cs-0062840

11. 19,21-dinorchol-4-en-20(22)-yn-3-one, 17-hydroxy-23,23-dimethyl-11-(4-(methyl(1-methylethyl)amino)phenyl)-, (11.beta.,17.alpha.)-

12. 19,21-dinorchol-4-en-20(22)-yn-3-one, 17-hydroxy-23,23-dimethyl-11-(4-(methyl(1-methylethyl)amino)phenyl)-, (11beta,17alpha)-

2.4 Create Date
2018-06-23
3 Chemical and Physical Properties
Molecular Weight 501.7 g/mol
Molecular Formula C34H47NO2
XLogP36.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count5
Exact Mass501.360679742 g/mol
Monoisotopic Mass501.360679742 g/mol
Topological Polar Surface Area40.5 Ų
Heavy Atom Count37
Formal Charge0
Complexity982
Isotope Atom Count0
Defined Atom Stereocenter Count7
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 2222344-98-9 / ORIC-101 API manufacturers, exporters & distributors?

ORIC-101 manufacturers, exporters & distributors 1

44

PharmaCompass offers a list of ORIC-101 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right ORIC-101 manufacturer or ORIC-101 supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred ORIC-101 manufacturer or ORIC-101 supplier.

PharmaCompass also assists you with knowing the ORIC-101 API Price utilized in the formulation of products. ORIC-101 API Price is not always fixed or binding as the ORIC-101 Price is obtained through a variety of data sources. The ORIC-101 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

ORIC-101

Synonyms

Chembl4161754, 2222344-98-9, Unii-vi6e2d3cyp, Oric101, Oric-101 [who-dd], Schembl20048238

Cas Number

2222344-98-9

Unique Ingredient Identifier (UNII)

VI6E2D3CYP

About ORIC-101

Glucocorticoid Receptor Antagonist ORIC-101 is a mifepristone-based steroidal glucocorticoid receptor (GR) antagonist with potential antineoplastic activity. Upon oral administration, ORIC-101 selectively binds to GRs, thereby inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers. Due to its reduced androgen receptor (AR) agonistic activity and improved cytochrome P450 2C8 (CYP2C8) and 2C9 (CYP2C9) inhibition profile, ORIC-101 may be useful in the treatment of AR-positive tumors with reduced potential for drug-drug interactions.

ORIC-101 Manufacturers

A ORIC-101 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ORIC-101, including repackagers and relabelers. The FDA regulates ORIC-101 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ORIC-101 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

ORIC-101 Suppliers

A ORIC-101 supplier is an individual or a company that provides ORIC-101 active pharmaceutical ingredient (API) or ORIC-101 finished formulations upon request. The ORIC-101 suppliers may include ORIC-101 API manufacturers, exporters, distributors and traders.

ORIC-101 GMP

ORIC-101 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of ORIC-101 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ORIC-101 GMP manufacturer or ORIC-101 GMP API supplier for your needs.

ORIC-101 CoA

A ORIC-101 CoA (Certificate of Analysis) is a formal document that attests to ORIC-101's compliance with ORIC-101 specifications and serves as a tool for batch-level quality control.

ORIC-101 CoA mostly includes findings from lab analyses of a specific batch. For each ORIC-101 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

ORIC-101 may be tested according to a variety of international standards, such as European Pharmacopoeia (ORIC-101 EP), ORIC-101 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ORIC-101 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty